Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type II Diabetes Mellitus
Phase PHASE2
Enrollment 285
Locations 21 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, once a week, subcutaneous injection) or placebo arm (once a week, subcutaneous injection) following initial dose-up titration that takes up to approximately 20 weeks. The primary end point is change in HbA1c levels from baseline (Week 0) to Week 36 following treatments in all participants.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: GL0034 Dose Level 1 — Dose 1, once a week
  • Drug: GL0034 Dose Level 2 — Dose 2, once a week
  • Drug: GL0034 Dose Level 3 — Dose 3, once a week
  • Drug: GL0034 Dose Level 4 — Dose 4, once a week
  • Drug: GL0034 Dose Level 5 — Dose 5, once a week
  • Drug: GL0034 Dose Level 6 — Dose 6, once a week
  • Other: Placebo — Placebo, once a week

Primary Outcomes

  • Change in HbA1c levels from baseline (Week 0) to Week 36 following treatments in all participants (Week 36)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-01-20
Completion: 2027-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 285 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Pharmaceutical Industries Limited
Contact Information
Study Contact:
Head, Regulatory Affairs
9122 66455645
Clinical.Trial@sunpharma.com
Interventions
  • Drug: GL0034 Dose Level 1 — Dose 1, once a week
  • Drug: GL0034 Dose Level 2 — Dose 2, once a week
  • Drug: GL0034 Dose Level 3 — Dose 3, once a week
  • Drug: GL0034 Dose Level 4 — Dose 4, once a week
  • Drug: GL0034 Dose Level 5 — Dose 5, once a week
Study Locations (21 sites)
Lynn Institute of the Ozarks, Little Rock, Arkansas 72204 United States
Family First Medical Research Center, Hialeah Gardens, Florida 33175 United States
Alliance for Multispecialty Research (AMR Clinical) - Wichita East, Lakeland, Florida 33803 United States
CNS Healthcare - Memphis (Clinical Neuroscience Solutions - Memphis), Lakeland, Florida 33803 United States
GTL Medical & Research Group, Miami, Florida 33173 United States
Florida Institute for Clinical Research LLC, Orlando, Florida 32835 United States
AMR Clinical, El Dorado, El Dorado, Kansas 67042 United States
AMR Clinical - Newton, Newton, Kansas 67114 United States
Lynn Health Science Institute - Oklahoma City, Oklahoma City, Oklahoma 73112 United States
Endolife Specialty Hospitals Pvt. Ltd., Guntur, Andhra Pradesh 522001 India
Eligibility Criteria
Inclusion Criteria: 1. Participant is willing and able to sign a written ICF or e-ICF. 2. Men or women ≥18 years of age at the time of signing ICF or e-ICF. 3. Participant was diagnosed with type II diabetes mellitus at least 180 days prior to the day of screening. 4. Participant has a HbA1c level of 7.0 - 10.5%, both inclusive, at the time of screening. 5. Participant has a stable BMI ≥27 kg/m2 for at least 90 days prior to screening. 6. Participant is able and willing to undergo fasting blood draw (i.e. at least 8 hours after last eating or drinking) as well as 7-point SMBG check for 3 consecutive days prior to designated scheduled visits by using a home glucometer that is provided by the study site. 7. Participant on stable daily doses of metformin for at least 90 days prior to screening. 8. Participant who are on metformin and not the following agents for at least 3 months prior to screening: DPP-4 inhibitors, alpha-glucosidase enzyme inhibitors, sulfonylureas, sodium-glucose transport 2 inhibitors, amylin analogues, thiazolidinediones, any insulin product, herbals, or ayurvedic agents. Participants are encouraged to follow the standard of care in their study regions, including appropriate diet and lifestyle modifications, rather than make abrupt change in the diabetic management prior to screening without consulting their physicians. 9. If participant is a woman of childbearing potential (WOCP)\*, she must agree to use a highly effective method of contraception during the study in conjunction with a barrier method of contraception, and continue the same contraception method at least one months after the last dose of study drug. Highly effective methods of contraception include one of the following: intrauterine device, injectable hormonal contraceptive, contraceptive patch or implant, partner's vasectomy, bilateral tubal occlusion, and sexual abstinence. \*WOCP includes women who are not surgically sterilized \[using hysterectomy/bilateral salpingectomy/bilateral oophorectomy\] or post-menopausal \[defined as 12 consecutive months of amenorrhea without an alternative medical cause\]. 10. Male participants with female partners of child-bearing potential must use a barrier method of contraception (e.g., condom) if not surgically sterile (i.e., vasectomy) during the study. In addition, male participants agree to use the same method of contraception for an additional 30 days after the last IP dose and refrain from donating sperm during this period. In the event that the female partner of the male participant becomes pregnant during the study period + 30 days after the last IP dose, an ICF will be provided to the female partner in order to monitor the female partner, pregnancy, and the newborn. 11. If participant is a WOCP, she must have a negative serum pregnancy test (SPT) at Screening and a negative urine pregnancy at baseline, with results available before IP administration. 12. Participant is willing and able to comply with the study protocol, visit schedule, and other study-related instructions and procedures. 13. Participant is willing and able to independently record the response on various scales and make entries using the e-Patient reported outcomes (ePRO) device. Exclusion Criteria: 1. Participants who have a history of type I diabetes mellitus. 2. A self-reported change in \>5% of body weight within 90 days before screening irrespective of medical records. 3. History of pancreatitis (acute or chronic) or \>3 hypoglycemic episodes (blood glucose level \<70 mg/dL or 3.9 mmol/L) within 90 days prior to screening. 4. Diagnosis of chronic kidney disease with estimated glomerular filtration rate \<60. 5. Poorly controlled hypertension with systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>100 mmHg. 6. Poorly controlled hypothyroidism defined as thyroid-stimulating hormone \>6 mIU/L or \<0.4 mIU/L. 7. Diabetes mellitus and/or obesity that is induced by endocrine disorders (e.g. Cushing Syndrome) or medication use (e.g. corticosteroids) as judged by the Investigator. 8. Previous surgical treatment for obesity (liposuction and/or abdominoplasty performed \>1 year before screening is allowed). Previous or planned (during the trial period) obesity treatment with surgery or a weight loss device. However, previous interventions that, due to reversal or removal, does not have any influence on the participant's weight, in the opinion of the Investigator, are allowed. 9. History of major depressive disorder within 2 years before randomization. 10. History of other severe psychiatric illnesses (i.e. schizophrenia, bipolar disorder). 11. Any lifetime history of a suicidal attempt. 12. Participants with any medical condition \[i.e. gastroparesis, uncontrolled gastroesophageal reflux disease, or diarrhea with or without a diagnosis of a diagnosis of irritable bowel syndrome\] that, in the opinion of the Investigator, can confound study efficacy assessments or safety concerns. 13. Participant had a myocardial infarction, unstable angina pectoris, or ischemic stroke within the past 6 months prior to IP administration. 14. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, sudden cardiac death, unexplained death, long QT syndrome, or death from a primary dysrhythmia potentially associated with QT prolongation in any family member. 15. Surgery scheduled for the trial duration period, except for very minor surgical procedures in the opinion of the Investigator. 16. Participants with active malignancy. Note: participants with past history of malignancy may be included if: * Participant has history of basal cell or in-situ squamous cell carcinoma of skin that has been adequately treated and resolved, per Investigator's judgement. * Participant has history of other malignancy that have been adequately treated with no evidence of recurrence/relapse within the last 5 years, per Investigator's judgement. 17. Presence of diabetic retinopathy \[both nonproliferative diabetic retinopathy and proliferative diabetic retinopathy\]) or maculopathy in either eye that was verified by a fundoscopic examination within 90 days prior to screening or during the study. 18. Known moderate to severe coronary, carotid, or peripheral vascular disease that has planned or will likely need revascularization during the study. 19. Participants with any other condition, which in the opinion of the Investigator, precludes participation in the study (either poses an unacceptable risk to the participant or interferes with assessment/interpretation of study outcomes). 20. Known hypersensitivity to the study IP or its excipients. 21. History of alcohol or drug abuse in the previous two years (Alcohol abuse in this study is defined as \>14 standard drinks per week in men or \>7 standard drinks per week in women ± a history of alcohol withdrawal symptoms ± institutionalized/hospitalized due to alcohol use ± binge drinking with \>5 standard drinks on a single occasion in men or \>4 standard drinks on a single occasion in women). 22. Participants are taking, or will start, medications with narrow therapeutic index such as digoxin, warfarin, etc, or those that will prolong QTc interval. 23. Participants received any medications for the treatment of type II diabetes mellitus other than those stated in the inclusion criteria within 90 days before screening. Short-term insulin treatment for a maximum of 7 days prior to screening is allowed. Prior insulin treatment for gestational diabetes is also allowed. 24. Participants who have used medications in the family of GLP-1 agonists in the past. 25. Treatment with any herbal diet supplements, over-the-counter diet medications as an attempt to lose weight within 90 days before screening. 26. Treatment with orlistat, lorcaserin, zonisamide, topiramate, phentermine, buproprion, or naltrexone that could promote weight loss within 90 days before screening. 27. Participa

IH, Brain Health, and T2D

NCT07173543
Recruiting
Conditions Type 2 Diabetes, Aging
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to use a randomized, placebo-controlled study design to rigorously examine the therapeutic potential of intermittent hypoxia (IH) for improving cerebrovascular health in older adults with and without type 2 diabetes mellitus (T2DM).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Intermittent Hypoxia 1 (IH1) — Intermittent Hypoxia 1 (IH1): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 8 weeks
  • Other: Intermittent Hypoxia 2 (IH2) — Intermittent Hypoxia 1 (IH2): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 4 weeks
  • Other: SHAM - normoxia — Participants will receive normoxia (no hypoxia) over 50 minutes.

Primary Outcomes

  • Internal Carotid Artery (ICA) shear-mediated dilation (Baseline and post 2-,4-,5-,6-, and 8-weeks)
  • Cerebral blood flow responsiveness (Baseline and after 50 minutes of IH or SHAM)
  • Cognitive function testing (Baseline and post 4- and 8-weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-22
Completion: 2028-06-30
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Darren P Casey
Collaborators: American Diabetes Association
Contact Information
Study Contact:
Darren Casey, PHD
13193841009
darren-casey@uiowa.edu
Darren P Casey, PhD
University of Iowa
Interventions
  • Other: Intermittent Hypoxia 1 (IH1) — Intermittent Hypoxia 1 (IH1): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 8 weeks
  • Other: Intermittent Hypoxia 2 (IH2) — Intermittent Hypoxia 1 (IH2): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 4 weeks
  • Other: SHAM - normoxia — Participants will receive normoxia (no hypoxia) over 50 minutes.
Study Locations (1 sites)
University of Iowa, Iowa City, Iowa 52242 United States
Eligibility Criteria
For 30 patients with documented Type 2 diabetes Inclusion Criteria: * Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures. * Age is \> or = 60 and \< or = 85 years of age * Documented Type 2 diabetes * Scoring 26 or higher on the MoCA test Exclusion criteria: * diagnosis of type 2 diabetes \< 1 year prior to enrollment * HbA1c \<6.5% or \>10.0% * body mass index \> 40 kg/m 2 * incident cardiovascular events in the last year (heart attack, stroke) * symptomatic coronary artery disease and/or heart failure * uncontrolled hypertension * obstructive sleep apnea * pulmonary disease * dementia * renal impairment with creatinine clearance (eGFR) of \<60 ml/min * smoking or history of smoking within past one year 30 nondiabetic control subjects will also be studied. Inclusion criteria: * Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures. * Age is \> or = 60 and \< or = 85 years of age * Scoring 26 or higher on the MoCA test Exclusion criteria: * Diagnosis of diabetes (Type 1 or Type 2) * body mass index \> 40 kg/m2 * incident cardiovascular events in the last year (heart attack, stroke) * symptomatic coronary artery disease and/or heart failure * uncontrolled hypertension * obstructive sleep apnea * pulmonary disease * dementia * renal impairment with creatinine clearance (eGFR) of \<60 ml/min * smoking or history of smoking within past one year
Conditions Hypertension (HTN)
Phase Not Applicable
Enrollment 1520
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of the Implementation of Effective Hypertension Management Approaches: Cleveland Clinic program is to improve blood pressure control for patients diagnosed with hypertension (HTN) and uncontrolled blood pressure, specifically defined as a blood pressure greater than 150/95, across all Cleveland Clinic Northeast Ohio primary care practices. The project will scale up the availability of resources for treating hypertension in 56 primary care practices within the Cleveland Clinic Health System in Northern Ohio, reaching up to approximately 3800 patients. This project will utilize evidence from a randomized controlled trial by Margolis et al.(1) to build upon Cleveland Clinic's existing team-based primary care provider (PCP) collaboration with pharmacists and advanced practice providers (APP) and will use a mechanism that allows titrating blood pressure medications based on patient-recorded home blood pressure readings.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Other: IN-HOME BP — A team-based approach with a primary care provider (PCP) collaborating with pharmacists and advanced practice providers (APP) and will use a mechanism (frequent follow-up- phone or virtual appointments) that allows titrating blood pressure medications based on patient-recorded home blood pressure readings.

Primary Outcomes

  • Systolic Blood Pressure Change (Patients will be followed for up to 33 months: 24-month implementation/intervention period and 9-month maintenance period.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-06
Completion: 2029-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1520 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Anita Misra-Hebert
Collaborators: Patient-Centered Outcomes Research Institute, The Cleveland Clinic
Contact Information
Study Contact:
Anita Misra-Hebert, MD, MPH, FACP
216-445-8542
MISRAA@ccf.org
Christopher Babuich, MD
440 204-7400
babiucc@ccf.org
Interventions
  • Other: IN-HOME BP — A team-based approach with a primary care provider (PCP) collaborating with pharmacists and advanced practice providers (APP) and will use a mechanism (frequent follow-up- phone or virtual appointments) that allows titrating blood pressure medications based on patient-recorded home blood pressure readings.
Study Locations (1 sites)
Cleveland Clinic, Cleveland, Ohio 44195 United States
Eligibility Criteria
Inclusion Criteria: * Hypertension diagnosis, aged 18-85 years old * Uncontrolled blood pressure, defined as a blood pressure reading of \> 150/95 Exclusion Criteria: * pregnant, stage 5 chronic kidney disease, End Stage Renal Disease, enrolled in hospice care
Conditions Hypertension (HTN)
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

High blood pressure (hypertension) is a leading risk factor for cardiovascular diseases and may contribute to poor health and premature death. The purpose of this research is to learn if a home-based isometric exercise programme combined with lifestyle change advice is a practical and acceptable method for people diagnosed with hypertension to manage their condition. Isometric exercise involves a muscle contraction without movement of the limbs and previous research has shown this may be effective for reducing blood pressure. Therefore, this study will explore the experiences, thoughts, attitudes, and barriers to participation. It will also examine the effect the isometric exercise has on blood pressure. Participants will undertake an isometric exercise programme using a wall squat position, 3 times per week, for 12 weeks. The exercise sessions will be completed at home with remote online supervision by an exercise professional. Lifestyle change advice will given in line with current guidelines to promote healthy behaviours to reduce high blood pressure. After 12 weeks, participants will be encouraged to continue with the wall squat exercise for a further 12-weeks unsupervised. Throughout the study, participants' blood pressure and daily activity will be recorded using a smartwatch device. Upon completion of the study, participants will be interviewed to gather their views and opinions on the programme. Changes in blood pressure will be evaluated at 12 and 24 weeks. By exploring whether lifestyle advice and an isometric exercise programme is a feasible and acceptable method for hypertensive people to manage their condition and how this influences blood pressure, this research may aid in the development of a strategy to manage hypertension.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: Isometric Exercise and Lifestyle Change Advice — The intervention consists of two distinct phases: • Intensive Phase (12 weeks) - a structured, high-support period involving three weekly supervised isometric exercise sessions and lifestyle change advice. The supervised exercise programme will consist of 4 × 2-minute bouts of wall squat exercise, with 2-minute rest periods between bouts. Participant squat height position will be based on individual calculations determined at baseline. Target rate of perceived exertion (RPE) for each bout will be: * Bout 1: RPE 4 (target range: 3.5-4.5) * Bout 2: RPE 5.5 (target range: 5-6) * Bout 3: RPE 7 (target range: 6.5-7.5) * Bout 4: RPE 8.5 (target range: 8-9) If the RPE falls outside the target zone for a given bout, participants will adjust their squat height accordingly. Lifestyle change advice will be given in booklet form in accordance with current NICE guidelines for hypertension. • Maintenance Phase (12-24 weeks) - focus on sustaining exercise and lifestyle behaviour changes
  • Behavioral: Lifestyle Change Advice — Lifestyle change advice given as per current standard care for hypertension

Primary Outcomes

  • Feasibility of Intervention (Baseline to 24 weeks)
  • Feasibility of Intervention (Baseline to 24 weeks)
  • Acceptability of Intervention (Post 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-02
Completion: 2028-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northumbria University
Collaborators: HealthWorks Newcastle Upon Tyne
Principal Investigators:
  • Gabriel Cucato, PhD (PRINCIPAL_INVESTIGATOR) - Northumbria University
Contact Information
Study Contact:
Helen Llewellyn, MSc
+447587033046
helen.llewellyn@northumbria.ac.uk
Gabriel Cucato, PhD
gabriel.cucato@northumbria.ac.uk
Helen Llewellyn, MSc
Northumbria University
Interventions
  • Behavioral: Isometric Exercise and Lifestyle Change Advice — The intervention consists of two distinct phases: • Intensive Phase (12 weeks) - a structured, high-support period involving three weekly supervised isometric exercise sessions and lifestyle change advice. The supervised exercise programme will consist of 4 × 2-minute bouts of wall squat exercise, with 2-minute rest periods between bouts. Participant squat height position will be based on individual calculations determined at baseline. Target rate of perceived exertion (RPE) for each bout will be: * Bout 1: RPE 4 (target range: 3.5-4.5) * Bout 2: RPE 5.5 (target range: 5-6) * Bout 3: RPE 7 (target range: 6.5-7.5) * Bout 4: RPE 8.5 (target range: 8-9) If the RPE falls outside the target zone for a given bout, participants will adjust their squat height accordingly. Lifestyle change advice will be given in booklet form in accordance with current NICE guidelines for hypertension. • Maintenance Phase (12-24 weeks) - focus on sustaining exercise and lifestyle behaviour changes
  • Behavioral: Lifestyle Change Advice — Lifestyle change advice given as per current standard care for hypertension
Study Locations (1 sites)
Northumbria University, Newcastle upon Tyne, NE1 8ST United Kingdom
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Arterial Hypertension (AH) in accordance with NICE guidelines. * Under pharmacological treatment for AH with antihypertensive drug, type and dose maintained for the previous four months. * Blood Pressure with values \<180 and \<110 mmHg for office systolic and diastolic BP, respectively. * Not currently engaged in any structured or supervised exercise training programme, including resistance, aerobic, or isometric exercise, defined as planned exercise performed ≥2 times per week at moderate or greater intensity, for at least three months prior to enrolment. Participants may engage in habitual physical activity; however, those meeting current physical activity recommendations (≥150 min·week-¹ of moderate-intensity or ≥75 min·week-¹ of vigorous-intensity activity, or an equivalent combination) will be excluded. Physical activity levels will be ascertained using the International Physical Activity Questionnaire (IPAQ). * Written informed consent provided. Exclusion Criteria: * Body mass index \>35 kg/m2. * Presence of cardiovascular disease beyond hypertension. * Known orthopaedic, musculoskeletal, or neurological conditions that restrain isometric exercise execution. * Presence of secondary hypertension * Inability to follow verbal instructions or complete study protocol
Conditions Locally Advanced or Metastatic Breast Ca...
Phase PHASE4
Enrollment 210
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, prospective, non-randomized, open-label, pharmacokinetic study, aiming to compare the plasma exposure of the payload (free-DXd) in patients treated by T-DXd for locally advanced or metastatic breast cancer according to their BMI. The primary objective is to compare plasma exposition of the payload (free-DXd) between overweight or obese (BMI\>25) and normal weight (BMI≤25) breast cancer patients during the first 3 cycles of Trastuzumab-Deruxtecan (T-DXd). A total of 210 patients will have to be enrolled in this study with the following repartition: N = 105 patients with a BMI ≤ 25 (normal weight patients). N = 105 patients with a BMI \> 25 (overweight or obese patients) with at least 30 obese patients (BMI\>30).

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Biological: Pharmacokinetics blood samples — Blood samples will be collected at different time points during the first four treatment cycles and at the end of T-DXd treatment or at 24 months after inclusion in case of T-DXd continuation beyond this time period.

Primary Outcomes

  • Primary Outcome Measure (From the 1st cycle of T-DXd (C1D1) to the end of the 3rd cycle of T-DXD (each cycle is 21 days) treatment or until an event (interruption or dose concession for toxicity) if it occurs before the 3rd cycle.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-10-15
Completion: 2029-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 210 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Claudius Regaud
Collaborators: Ligue contre le cancer, France
Contact Information
Study Contact:
Florence DALENC, MD, Prof
+33531155104
dalenc.florence@iuct-oncopole.fr
Anne Patsouris, MD
+33241352700
anne.patsouris@ico.unicancer.fr
Institut de Cancérologie de l'Ouest - Site Angers
Sylvain Ladoire, MD,Prof
+33380737506
sladoire@cgfl.fr
Centre Georges François Leclerc
Interventions
  • Biological: Pharmacokinetics blood samples — Blood samples will be collected at different time points during the first four treatment cycles and at the end of T-DXd treatment or at 24 months after inclusion in case of T-DXd continuation beyond this time period.
Study Locations (11 sites)
Institut de Cancérologie de l'Ouest - Site Angers, Angers, France
Centre Georges François Leclerc, Dijon, France
Centre Oscar Lambret, Lille, France
Institut Paoli Calmettes, Marseille, France
CHU de Nîmes, Nîmes, France
Institut Curie - Site Paris, Paris, France
Centre Eugène Marquis, Rennes, France
Institut de Cancérologie de l'Ouest - Site Saint Herblain, Saint-Herblain, France
Centre Paul Strauss, Strasbourg, France
IUCT-O, Toulouse, France
Eligibility Criteria
Inclusion Criteria: 1. Women (or men) aged ≥ 18 years on the day of signing the informed consent with histologically proven breast cancer. 2. Metastatic or locally advanced breast cancer with overexpression/amplification HER2 (IHC +++ or ++ and positive-hybridation in situ) or low HER2 expression (IHC + or ++ and negative-hybridation in situ) and may be ultra-low (in first line, in case of approval). 3. Patient eligible for Trastuzumab-Deruxtecan (T-DXd). 4. Concomitant administration of pertuzumab may be accepted in case of approval in first line for HER2- overexpressed/amplified locally advanced or metastatic breast cancer. 5. Female subjects of childbearing potential must have a negative pregnancy test within 72 hours prior to receiving the first dose of study treatment. 6. Female subjects of childbearing potential must be willing to follow at least one method of contraception or be surgically sterile, or abstain from heterosexual activity for the duration of the study and until 7 months after the last dose of study treatment. Subjects of childbearing potential are those who have not been surgically sterilized and who had menstruation in the last 12 months. Note: Abstinence is acceptable if it is the subject's usual lifestyle and preferred method of contraception. 7. Male subjects must agree to use at least one method of contraception for the duration of the study and until 4 months after the last dose of study treatment. Note: Abstinence is acceptable if it is the subject's usual lifestyle and preferred method of contraception. 8. Signed written informed consent. 9. Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol. 10. Patient affiliated to a Social Health Insurance in France. Exclusion Criteria: 1. Peripheral venous access making blood samples difficult. 2. Patients unable to receive T-DXd treatment at a dose of 5.4 mg/kg in cycle 1 (whatever the reason) 3. Patients with known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. 4. Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with completion of the study. 5. Patient pregnant, or breast-feeding. 6. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure. 7. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice). 8. Concurrent participation in an experimental drug study. 9. Patient with a known history of hypersensitivity to the active substance of T-DXd or to any of the excipients listed in the SmPC of T-DXd. 10. Patient with severe hepatic impairment defined by TGO and/or TGP \> 5 x ULN and Total bilirubin \> 1.5 x ULN.
Conditions Preeclampsia, Postpartum, Endothelial In...
Phase PHASE1, PHASE2
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

\--- Why Is This Study Being Done? Women who have preeclampsia during pregnancy face a much higher risk of heart disease later in life. Preeclampsia is a serious pregnancy condition that causes high blood pressure and damages blood vessels. Even after the baby is born, the blood vessels do not fully heal on their own, which can lead to heart problems/cardiovascular years later. This study tests whether a new treatment called exosomes can help repair damaged blood vessels in women who had preeclampsia. Exosomes are tiny particles that come from stem cells and contain healing substances that may help blood vessels work better. \--- What Will Happen in This Study? This study will include 80 women who recently gave birth and had preeclampsia during their pregnancy. Half of the women will receive the exosome treatment through an IV, and half will receive a placebo (a substance with no active treatment). \--- What Will Participants Need to Do? Participants will: * Have blood tests and other health checks * Receive one treatment through an IV * Return for follow-up visits at 1 week after treatment * Have tests to check how well their blood vessels are working Who Can Join This Study? Women who: * Recently gave birth (within 1-2 weeks) * Had preeclampsia during their last pregnancy * Are healthy enough to participate * Can give permission to join the study What Are the Possible Benefits and Risks? The treatment may help repair blood vessel damage and reduce the risk of future heart disease. The exosome treatment appears to be safe based on other studies, but like any medical treatment, there may be side effects. \--- How Long Will the Study Last? The main treatment happens during one visit, with follow-up visits for 1 week to check on participants' health and see if the treatment is working. This research may lead to new ways to protect women's heart health after pregnancy complications.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Mesenchymal Stem Cell-Derived Exosomes — Mesenchymal stem cell-derived exosomes isolated from adipose-derived stem cells (ASC). The exosomes contain bioactive molecules including microRNAs (particularly miR-126-3p), proteins, and lipids that promote endothelial repair and regeneration. The product is manufactured under GMP conditions and administered as a single Intravenous or Intramuscular infusion.
  • Other: Placebo (Sterile Saline Solution) — Sterile saline solution (0.9% sodium chloride) administered Intravenous or Intramuscular as placebo control. The volume and administration method are identical to the active treatment to maintain blinding.

Primary Outcomes

  • Change in Endothelial Function Biomarker (miR-126-3p) (Baseline and 1 week post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-07-01
Completion: 2026-09-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitas Padjadjaran
Collaborators: Hasan Sadikin General Hospital, Dr Cipto Mangunkusumo General Hospital, Dr. Sardjito Hospital, Yogyakarta
Principal Investigators:
  • Akhmad Y Pramatirta, M.D., Ph.D (PRINCIPAL_INVESTIGATOR) - Dr. Hasan Sadikin Central General Hospital
Contact Information
Study Contact:
Prima N Fauziah, S.Si., M.Si.
+62 85721368609
primanandafauziah@gmail.com
Nurul Azizah, S.Tr.Keb.
+62 81312971480
nurul19012@mail.unpad.ac.id
Akhmad Y Pramatirta, M.D., Ph.D.
+62 81320403090
akhmad.yogi@unpad.ac.id
Dr. Hasan Sadikin Central General Hospital
Interventions
  • Biological: Mesenchymal Stem Cell-Derived Exosomes — Mesenchymal stem cell-derived exosomes isolated from adipose-derived stem cells (ASC). The exosomes contain bioactive molecules including microRNAs (particularly miR-126-3p), proteins, and lipids that promote endothelial repair and regeneration. The product is manufactured under GMP conditions and administered as a single Intravenous or Intramuscular infusion.
  • Other: Placebo (Sterile Saline Solution) — Sterile saline solution (0.9% sodium chloride) administered Intravenous or Intramuscular as placebo control. The volume and administration method are identical to the active treatment to maintain blinding.
Study Locations (1 sites)
Dr. Hasan Sadikin Central General Hospital, Bandung, West Java 40161 Indonesia
Eligibility Criteria
Inclusion Criteria: * Postpartum * Confirmed diagnosis of preeclampsia in the last pregnancy * Postpartum period of first week and second week * Able to provide informed consent Exclusion Criteria: * History of chronic hypertension prior to pregnancy * Major cardiovascular disease history * Active systemic infection * Endothelial Injury history * Active smoking status including vape, alcohol, drug addiction.
Conditions Type 2 Diabetes Mellitus (T2DM), Pregnan...
Phase NA
Enrollment 70
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to compare patient adherence to blood sugar monitoring during pregnancy using two different measurement methods in pregnancies complicated by pregestational type 2 diabetes (T2DM). Pregnant patients with T2DM are at risk of having larger babies, babies with low sugar levels in the first 24 hours of life, higher rates of cesarean delivery, stillbirth (death of baby inside the womb), and hypertensive or high blood pressure disorders of pregnancy, such as preeclampsia. Prior studies have shown that treating high blood sugars in pregnancy with medications can reduce these risks. To determine the amount of medication needed, recording of blood sugar levels is necessary. This trial aims to determine whether continuous blood sugar monitors have improved patient recording of blood sugar levels over finger stick blood sugar measurements. Patients involved in the study will be assigned to either: 1. Fingerstick glucose monitoring (FSG) 2. Continuous glucose monitoring (CGM) Patients will be randomize in a 1:1 ratio. FSG Group: blood sugar is tested four times daily - once fasting and two hours after every meal (post-prandial). Blood will be tested using a glucometer, and values will be recorded in a blood sugar log from the time of enrollment to the time of delivery. CGM Group: A CGM sensor will be placed on the patient's arm for blood sugar collection every 3-5 minutes. This data is sent to a phone application from the time of enrollment to the time of delivery. These sensors will need to be replaced every 14 days. Percent adherence will be recorded from the time you were randomized to a study group until delivery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Continuous glucose monitor — Continuous glucose monitors are sensors that detect interstitial blood glucose measurements and relay values from their sensor to a receiver (typically a cell phone) to document values every 5 minutes.
  • Device: Glucometer — Glucometer measurement involves a patient performing a finger stick with a lancet to draw blood. They then apply blood to a test strip which is analyzed by a glucometer. The glucose measurement provided by the glucometer is then recorded by the patient in a glucose log.

Primary Outcomes

  • Patient glucose monitoring adherence (through pregnancy episode, typically 20-35 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2026-03-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Thomas Jefferson University
Collaborators: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Contact Information
Study Contact:
Brandy Firman
215-955-8401
brandy.firman@jefferson.edu
Brandy Firman
215-955-8401
brandy.firman@jefferson.edu
Jefferson Health New Jersey
Brandy Firman
215--955-8401
brandy.firman@jefferson.edu
Thomas Jefferson University
Interventions
  • Device: Continuous glucose monitor — Continuous glucose monitors are sensors that detect interstitial blood glucose measurements and relay values from their sensor to a receiver (typically a cell phone) to document values every 5 minutes.
  • Device: Glucometer — Glucometer measurement involves a patient performing a finger stick with a lancet to draw blood. They then apply blood to a test strip which is analyzed by a glucometer. The glucose measurement provided by the glucometer is then recorded by the patient in a glucose log.
Study Locations (2 sites)
Jefferson Health New Jersey, Sewell, New Jersey 08080 United States
Thomas Jefferson University, Philadelphia, Pennsylvania 19107 United States
Eligibility Criteria
Inclusion Criteria: * singleton pregnancies * fetuses without anomalies * diagnosis of Type 2 diabetes * initiation of prenatal care at \<20 weeks gestation Exclusion Criteria: * diagnosis of Type 1 diabetes * allergy to insulin * inability to wear a continuous glucose monitor
Conditions Cataract, Glaucoma, Ocular Hypertension
Phase PHASE3
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Bimatoprost Implant System — Bimatoprost Implant System used in combination with the SpyGlass IOL
  • Device: SpyGlass IOL — SpyGlass Intraocular Lens
  • Drug: Timolol Maleate Ophthalmic Solution, 0.5% — Timolol Maleate Ophthalmic Solution, 0.5% BID
  • Device: Commercial IOL — Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens

Primary Outcomes

  • Mean IOP Reduction from Baseline (mmHg) (Weeks 2 and 6, and Month 3)
  • BCDVA 20/40 or better (Month 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-10-15
Completion: 2031-03-31
Eligibility
Age: 22 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SpyGlass Pharma, Inc.
Principal Investigators:
  • Paul Yoo, OD (STUDY_CHAIR) - SpyGlass Pharma
Contact Information
Study Contact:
Director, Clinical Affairs
949-284-6904
clinical@spyglasspharma.com
Clinical Research Coordinator
832-553-7100
jmaguilar@houstoneye.com
Houston Eye Associates
Interventions
  • Drug: Bimatoprost Implant System — Bimatoprost Implant System used in combination with the SpyGlass IOL
  • Device: SpyGlass IOL — SpyGlass Intraocular Lens
  • Drug: Timolol Maleate Ophthalmic Solution, 0.5% — Timolol Maleate Ophthalmic Solution, 0.5% BID
  • Device: Commercial IOL — Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens
Study Locations (1 sites)
Houston Eye Associates, Houston, Texas 77025 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension * Planned removal of cataract * Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception Exclusion Criteria: * Uncontrolled systemic disease * History of incisional/refractive corneal surgery * Any glaucoma diagnosis other than OHT, open-angle, pseudoexfoliative, or pigmentary glaucoma * History of incisional glaucoma surgery or intraocular injections * Other ocular diseases, pathology, or conditions
Conditions Type 2 Diabetes Mellitus (T2DM), Semaglu...
Phase PHASE4
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants and explored the molecular mechanisms of action, providing high-quality evidence-based support for the timing and targets of intervention in this population.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: semaglutide — The semaglutide group received weekly subcutaneous semaglutide (0.25 mg for weeks 1-2, 0.5 mg for weeks 3-4, and 1.0 mg for weeks 5-12).
  • Behavioral: caloric restriction — The caloric restriction group followed a gender-specific daily caloric restriction (1,500-1,800 kcal for males; 1,200-1,500 kcal for females).

Primary Outcomes

  • HbA1c (From enrollment to the end of treatment at 12 weeks)
  • FPG (From enrollment to the end of treatment at 12 weeks)
  • 2hPG (From enrollment to the end of treatment at 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2023-02-10
Completion: 2026-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital of Nanchang University
Contact Information
Study Contact:
Jianping Liu
+8679186274551
ndefy14105@ncu.edu.cn
Jianping Liu
+8679186274551
ndefy14105@ncu.edu.cn
Minde road No.1
ndefy14105@ncu.edu.cn
Minde road No.1
Interventions
  • Drug: semaglutide — The semaglutide group received weekly subcutaneous semaglutide (0.25 mg for weeks 1-2, 0.5 mg for weeks 3-4, and 1.0 mg for weeks 5-12).
  • Behavioral: caloric restriction — The caloric restriction group followed a gender-specific daily caloric restriction (1,500-1,800 kcal for males; 1,200-1,500 kcal for females).
Study Locations (1 sites)
Minde road No.1, Jiangxi, Nanchang 330000 China
Eligibility Criteria
Inclusion Criteria: 1. Age 18-75 years; 2. BMI≥25 kg/m²; 3. Diagnosed as type 2 diabetes mellitus patients according to the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)"; 4. HbA1c≤8.5%; 5. Duration of diabetes ≤3 months, and no use of antihyperglycemic drugs; 6. Willing to participate in this study, and after full informed consent, agrees to strictly follow the treatment plan and promises to attend follow-up visits on time, and signs the informed consent form. Exclusion Criteria: 1. BMI \< 25 kg/m²; 2. Age \< 18 years, or \> 75 years; 3. History of type 1 diabetes, acute pancreatitis, or diabetes secondary to pancreatectomy; 4. History of bariatric surgery or planned bariatric surgery, or currently attempting weight loss within the past 3 months, or use of weight-loss medications within the past 3 months; 5. Use of GLP-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, or other related drugs within the past 3 months; 6. Pregnant or breastfeeding women, or those planning to conceive during the study period; 7. Patients with severe diseases of important organ systems, such as severe cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, renal insufficiency, hematologic diseases, neurological diseases, or malignancies; 8. Personal or family history of medullary thyroid carcinoma; 9. Patients with severe mental disorders or communication barriers that prevent accurate understanding of the study content and compliance with the trial procedures.
Conditions Hypertension, Dyslipidemia, Diabetes Mel...
Phase NA
Enrollment 72
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Experimental - 12 Week P3-EX Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants — UConn Graduate Research Assistants will provide patients with virtual weekly oversight to follow their P3-EX unsupervised exercise program for 12 weeks. Patients will choose the location and the FITT of exercise they prefer. UConn Graduate Research Assistants will provide all patients with a 12-week exercise program information packet containing progressive FITT exercise recommendations for their exercise program. Patients will use an exercise diary called the Timeline Followback for Exercise to record the FITT of exercise daily. Patients will attend two virtual study visits led by UConn Graduate Research Assistants during the first week and midway through the intervention to receive standardized guidance on how they are doing following their exercise program. UConn Graduate Research Assistants will email all patients weekly to provide their progressive FITT exercise recommendations and summary reports of their Timeline Followback for Exercise recordings.
  • Behavioral: Active Control - 12 Week ACSM-PAVS Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants — University of Connecticut (UConn) Graduate Research Assistants will provide patients with virtual weekly oversight to follow their ACSM-PAVS unsupervised exercise program for 12 weeks. Patients will choose the location and the FITT of exercise they prefer. UConn Graduate Research Assistants will provide all patients with a 12-week exercise program information packet containing progressive FITT exercise recommendations for their exercise program. Patients will use an exercise diary called the Timeline Followback for Exercise to record the FITT of exercise daily. Patients will attend two virtual study visits led by UConn Graduate Research Assistants during the first week and midway through the intervention to receive standardized guidance. UConn Graduate Research Assistants will email all patients weekly to provide their progressive FITT exercise recommendations and summary reports of their Timeline Followback for Exercise recordings.

Primary Outcomes

  • Feasibility and Acceptability of Prioritize Personalize Prescribe EXercise (P3-EX) (Within 48 hours following the delivery of P3-EX and ACSM-PAVS)
  • Feasibility and Acceptability of Prioritize Personalize Prescribe EXercise (P3-EX) (Within 48 hours following the delivery of P3-EX and ACSM-PAVS)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-30
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Connecticut
Collaborators: Hartford HealthCare, UConn Health
Principal Investigators:
  • Linda S Pescatello, PhD (PRINCIPAL_INVESTIGATOR) - Department of Kinesiology, University of Connecticut
  • Antonio B Fernandez, MD (PRINCIPAL_INVESTIGATOR) - Hartford HealthCare Heart & Vascular Institute, Hartford Hospital
  • Gregory Panza, PhD (STUDY_DIRECTOR) - Department of Research Administration, Hartford HealthCare
Contact Information
Study Contact:
Alexander J Wright, MS
(860) 486-6814
Alexander.Wright@hhchealth.org
Linda S Pescatello, PhD
(860) 486-0008
linda.pescatello@uconn.edu
Peter F Robinson, MD
(860) 679-3343
perobinson@uchc.edu
UConn Health
Interventions
  • Behavioral: Experimental - 12 Week P3-EX Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants — UConn Graduate Research Assistants will provide patients with virtual weekly oversight to follow their P3-EX unsupervised exercise program for 12 weeks. Patients will choose the location and the FITT of exercise they prefer. UConn Graduate Research Assistants will provide all patients with a 12-week exercise program information packet containing progressive FITT exercise recommendations for their exercise program. Patients will use an exercise diary called the Timeline Followback for Exercise to record the FITT of exercise daily. Patients will attend two virtual study visits led by UConn Graduate Research Assistants during the first week and midway through the intervention to receive standardized guidance on how they are doing following their exercise program. UConn Graduate Research Assistants will email all patients weekly to provide their progressive FITT exercise recommendations and summary reports of their Timeline Followback for Exercise recordings.
  • Behavioral: Active Control - 12 Week ACSM-PAVS Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants — University of Connecticut (UConn) Graduate Research Assistants will provide patients with virtual weekly oversight to follow their ACSM-PAVS unsupervised exercise program for 12 weeks. Patients will choose the location and the FITT of exercise they prefer. UConn Graduate Research Assistants will provide all patients with a 12-week exercise program information packet containing progressive FITT exercise recommendations for their exercise program. Patients will use an exercise diary called the Timeline Followback for Exercise to record the FITT of exercise daily. Patients will attend two virtual study visits led by UConn Graduate Research Assistants during the first week and midway through the intervention to receive standardized guidance. UConn Graduate Research Assistants will email all patients weekly to provide their progressive FITT exercise recommendations and summary reports of their Timeline Followback for Exercise recordings.
Study Locations (3 sites)
UConn Health, Farmington, Connecticut 06030 United States
Hartford HealthCare, Hartford, Connecticut 06102 United States
University of Connecticut, Storrs, Connecticut 06269 United States
Eligibility Criteria
Physician Inclusion Criteria 1. Practicing medical doctors employed at the study recruitment sites 2. Do not recommend written exercise programs or plans to their patients, nor refer them to exercise clinics or exercise professionals 3. Are willing to recruit two of their patients to deliver Prioritize Personalize Prescribe EXercise (P3-EX) and American College of Sports Medicine Physical Activity Vital Sign (ACSM PAVS) Patient Inclusion Criteria 1. Sedentary: have not performed planned, structured physical activity at moderate intensity for ≥30 minutes on ≥3 days per week in the last 3 months 2. Adults: ≥18 and ≤64 yrs 3. ≥1 cardiovascular disease risk factors: Having obesity, hypertension, dyslipidemia, and/or diabetes (or prediabetes) * Obesity: BMI ≥30 kg/m2 or WC \>102 cm (40 in) for men and \>88 cm (35 in) for women * Hypertension: Systolic BP ≥130 mm Hg and/or diastolic BP ≥80 mm Hg, or on antihypertensive medication * Dyslipidemia: LDL-C ≥130 mg/dL (3.37 mmol/L), or HDL-C \<40 mg/dL (1.04 mmol/L) in men and \<50 mg/dL (1.3 mmol/L) in women, or non-HDL-C ≥160 mg/dL (4.14 mmol/L), or on lipid-lowering medication, or TC ≥200 mg/dL (5.18 mmol/L) * Diabetes (or prediabetes): FBG ≥100 mg/dL or HbA1c ≥5.7%, or on medication for diabetes 4. Healthy: Having no signs or symptoms of or have cardiovascular or renal disease, or other diseases or health conditions that significantly limit physical activity engagement 5. Not pregnant or lactating 6. Not a cigarette smoker or quit smoking ≥6 months ago 7. Consume \<2 alcoholic drinks daily 8. Able to use a computer or phone with internet access 9. Fluent in English 10. Willing to maintain their medication routine and habitual diet and not follow other exercise or nutrition programs. Patient Exclusion Criteria 4a. Have pain or discomfort in the chest, neck, jaw, or arms; dizziness or syncope; shortness of breath at rest or with mild exertion; unusual fatigue or shortness of breath with usual activities; orthopnea; ankle edema; intermittent claudication; palpitations; or known heart murmur 4b. Stroke or cancer survivors or currently have cancer, chronic obstructive pulmonary disease, musculoskeletal injury, chronic back pain, depression, dementia, or other diseases or health conditions that are deemed to significantly limit physical activity engagement.
Conditions Pulmonary Hypertension, Heart Failure Wi...
Phase NA
Enrollment 750
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH) associated with left heart disease (LHD). This randomized control trial will compare the investigational device (The Enhancor System) to control (medical therapy.) Participants who will consist of patients with chronic heart failure (HF) who are receiving maximally tolerated guideline-directed medical therapy (GDMT) for left heart failure, are clinically stable, and who have been diagnosed with CpcPH by right heart catheterization (RHC), will be treated with PADN and followed for 3 years.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Pulmonary Artery Denervation (PADN) — In patients randomized to Intervention, a Contrast pulmonary artery (PA) angiography will be performed to identify the pulmonary artery bifurcation and measure the PA diameter. Once the anatomy is deemed suitable, a radiofrequency ablation catheter will be introduced into the ostium of the left PA and the distal bifurcation of the main PA. The catheter will be maneuvered within the PA to deliver energy circumferentially, ensuring tight electrode contact with the endovascular surface. Approximately three ablations will be performed at a target temperature of 50 °C (range 45-55 °C) for 120 seconds each at both the left PA ostium and the distal main PA bifurcation. All patients enrolled in this clinical study will following the Guideline-Directed Medical Therapy (GDMT)
  • Device: Sham procedure control — In patients randomized to a placebo-procedure, a script will be followed for approximately 20 minutes to simulate the PADN procedure. All patients enrolled in this clinical study will following the Guideline-Directed Medical Therapy (GDMT)

Primary Outcomes

  • Primary Efficacy Endpoint (Immediately after the randomization to last enrolled patient reaches 12-month follow-up)
  • Primary Safety Endpoint (30-days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-30
Completion: 2031-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 750 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pulnovo Medical, Inc.
Principal Investigators:
  • Gregg W. Stone (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine at Mount Sinai
Contact Information
Study Contact:
MOFFETT LAURA MARY GINTANT
+1 952 303 2821
laura.moffett@pulnovomed.com
Mark Gu
+08 13774217349
mark.g@pulnovomed.com
Sorajja
(612) 863-3900
paul.sorajja@allina.com
Banner - University Medical Center Tucson
Interventions
  • Device: Pulmonary Artery Denervation (PADN) — In patients randomized to Intervention, a Contrast pulmonary artery (PA) angiography will be performed to identify the pulmonary artery bifurcation and measure the PA diameter. Once the anatomy is deemed suitable, a radiofrequency ablation catheter will be introduced into the ostium of the left PA and the distal bifurcation of the main PA. The catheter will be maneuvered within the PA to deliver energy circumferentially, ensuring tight electrode contact with the endovascular surface. Approximately three ablations will be performed at a target temperature of 50 °C (range 45-55 °C) for 120 seconds each at both the left PA ostium and the distal main PA bifurcation. All patients enrolled in this clinical study will following the Guideline-Directed Medical Therapy (GDMT)
  • Device: Sham procedure control — In patients randomized to a placebo-procedure, a script will be followed for approximately 20 minutes to simulate the PADN procedure. All patients enrolled in this clinical study will following the Guideline-Directed Medical Therapy (GDMT)
Study Locations (6 sites)
Banner - University Medical Center Tucson, Tucson, Arizona 85711 United States
Cardiovascular Institute of the South, Houma, Louisiana 70360 United States
Henry Ford Hospital, Detroit, Michigan 48202 United States
Cleveland Clinic, Cleveland, Ohio 44109 United States
Oklahoma Heart Institute, Tulsa, Oklahoma 74104 United States
University of Pittsburgh Medical Center, Mechanicsburg, Pennsylvania 17050 United States
Eligibility Criteria
Inclusion Criteria: 1. Subject is ≥18 and ≤85 years of age 2. Subject is diagnosed with chronic HF due to left-sided heart disease for at least 6 months prior to screening (regardless of LVEF), and remains symptomatic despite maximally tolerated class I GDMT for left heart failure and CRT as appropriate per US or EU guidelines according to region of enrollment 3. Subject is clinically stable, defined as: * No hospitalizations for heart failure for at least 1 month; no major changes in societal guideline-recommended class I oral GDMT for left heart failure for at least 1 month; no CRT or ICD implant in the prior 3 months; and no anticipated major changes in any HF-GDMT (other than possibly diuretic dose) or planned cardiac rhythm management device implantation after the procedure * SBP is ≥90 and ≤160 mmHg and resting HR is ≥50 and ≤100 bpm (≤110 bpm for atrial fibrillation) 4. PASP (RVSP) is ≥30 mmHg on the baseline TTE. 5. Subject has New York Heart Association (NYHA) class II, III or IVa symptoms (IVa is defined as symptoms with minimal exertion or at rest, but the patient is able to ambulate and does not require continuous intravenous medications). 6. Subject has 6MWD at baseline ranging from 100 to 450 m limited by dyspnea or fatigue and not orthopedic or other non-HF-related issues 7. Subject has NT-proBNP ≥600 pg/mL for patients with LVEF ≤40% or ≥200 pg/mL for patients with LVEF \>40% at the time of screening (a central lab will be made available for sites that cannot measure NT-proBNP) 8. Subject is able and willing to follow all aspects of the research protocol including medication compliance and follow-up visits and testing. 9. Subject or the subject's legally designated representative signs an IRB/EC approved informed consent form prior to study participation. Exclusion Criteria: 1. Subject has a life expectancy of less than 1 year due to non-cardiovascular causes. 2. Subject has known hypertrophic cardiomyopathy with either left ventricular (LV) outflow tract obstruction or systolic anterior motion (SAM) of the anterior leaflet of the mitral valve; pericardial disease; or infiltrative or active inflammatory myocardial disease, including known amyloidosis 3. Subject has severe stenosis or regurgitation of any heart valve, moderate or severe stenosis of the aortic valve, or any degree of stenosis of the pulmonic valve 4. Subject has symptomatic carotid stenosis, or transient ischemic attack (TIA) or stroke in the prior 30 days or any prior stroke with a permanent residual deficit with modified Rankin Scale (mRS) score ≥4 5. Subject has any prior intracranial hemorrhage with or without a residual deficit, or any known intracranial pathology pre-disposing to bleeding (e.g. mass, AV fistula, aneurysm, etc.) 6. Subjects with a known bleeding diathesis or who will refuse blood transfusions 7. Subjects allergic to heparin (including heparin induced thrombocytopenia), unless bivalirudin or argatroban can be used for procedural anticoagulation 8. Subjects with life threatening allergy to contrast dye that cannot be adequately pre-medicated, or any prior contrast-related anaphylaxis 9. Subject has congenital heart disease other than mitral valve prolapse or a PFO 10. Subject had coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in the prior 6 months or is anticipated to undergo CABG or PCI within 12 months after randomization. 11. Subject has any pacemaker with an intracardiac sensing or pacing lead or wire implanted in the prior 3 months, or CardioMEMS HF System or other intracardiac pressure monitoring system, or cardiac contractility modulation system or baroreceptor activation therapy implanted within the prior 3 months, or any plans to implant any of these devices within 12 months after the procedure. 12. Subject has undergone atrial fibrillation ablation within the prior 6 months or is anticipated to undergo atrial fibrillation ablation within 12 months after randomization. 13. Subject has undergone heart valve surgery or transcatheter valve intervention within the prior 6 months or is anticipated to undergo heart valve surgery or transcatheter valve intervention (e.g., valve repair or replacement, valvuloplasty) within 12 months after randomization. 14. Subject has any tricuspid or pulmonic valve implants (implanted annuloplasty rings are allowed). 15. Subject has an inferior vena cava (IVC) filter implant. 16. Subject has received a prior heart or heart-lung transplantation or is listed for heart or heart-lung transplantation or is anticipated to receive a ventricular assist device (VAD) implant within 6 months after randomization. 17. Subjects with intracardiac thrombus on TTE. 18. Subjects with pericardial effusion ≥10 mm on TTE 19. Subject's PH is predominantly due to WHO Group 1, 3, 4, or 5. Note: Multifactorial features of PH may be present, but the predominant diagnosis must be WHO Group 2 CpcPH. 20. Subject has been treated with any group 1 PAH-targeted drugs, including sotatercept, within the prior month or is planned to receive such therapy after randomization. 21. Subject is anticipated to undergo any surgery within 6 months after randomization (other than minor surgeries requiring only local anesthesia). 22. Subject has severe renal insufficiency (eGFR \<30 mL/min/1.73m2 by the CKD-EPI formula, or on dialysis). 23. Subject has severe liver insufficiency (Child-Pugh classification C). 24. Subject has platelet count \<100 × 109/L. 25. Subject has systemic inflammatory or other disease requiring long-term use of oral glucocorticoids or immunosuppressants. 26. Subject has active infection requiring oral or intravenous antibiotics. 27. Subject has a body mass index (BMI) \>45 kg/m². 28. Subjects with severe respiratory disease, defined as any disorder of the respiratory system with diffusing capacity of the lungs for carbon monoxide (DLCO) \<40% AND total lung capacity (TLC) \<60% AND forced expiratory volume in one second (FEV1) \<70% by plethysmography; OR who require ambulatory or long-term oxygen therapy 29. Subject has known severe untreated sleep apnea. Note: Subjects with sleep apnea treated with CPAP/BiPAP for at least the prior 3 months are not excluded. 30. Subjects with pulmonary embolism or deep vein thrombosis in the prior 6 months. 31. Subject is a pregnant or breastfeeding woman, or a woman planning to become pregnant within one year. Women of child-bearing potential must have a negative pregnancy test within 1 week of randomization. 32. Subject is participating in another clinical trial of an investigational drug or device that has not reached its primary endpoint. 33. Subject has severe cachexia/frailty, substance abuse, or any other condition that the investigator believes may affect the subject's ability to comply with or complete all the study requirements including follow-up visits. 34. Subject is a member of a vulnerable population who, in the judgment of the investigator, is unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include individuals with mental disability, children, impoverished persons, persons in prisons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations may also include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.
Conditions Apparent Resistant Hypertension, Hyperte...
Phase NA
Enrollment 142
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-center, open-label, randomized clinical trial conducted at the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. The study evaluates a simplified treatment strategy for patients with apparent resistant hypertension, comparing fixed triple combination therapy (perindopril, indapamide, and amlodipine) with usual care using multiple separate antihypertensive drugs. The primary objective is to compare 24-hour blood pressure control as measured by ABPM at 12 weeks between the two treatment strategies. Enrollment began on July 15, 2023, and this study was registered retrospectively.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Triple Fixed-Dose Combination (Perindoprile/Indapamide/Amlodipine) — Participants receive a fixed-dose tablet containing perindopril 10 mg, indapamide 2.5 mg, and amlodipine 10 mg administered once daily for 12 weeks. Randomized participants in this group discontinue their previous antihypertensive medications and replace them with the single-pill triple fixed-dose combination. Treatment adjustments may be made if required according to office blood pressure measurements
  • Drug: Usual Care Antihypertensive Regimen — Participants continue their usual antihypertensive therapy, consisting of up to five drug classes administered as separate tablets. Medication types and doses are adjusted by the investigator as needed to achieve office blood pressure control, following standard clinical practice. Treatment modifications are permitted throughout the 12-week study period according to clinical judgment and blood pressure response.

Primary Outcomes

  • Rate of 24-hour Blood Pressure Control Measured by ABPM at 12 weeks (12 weeks)
  • Rate of 24-hour Blood Pressure Control Measured by Ambulatory Blood Pressure Monitoring (ABPM) at 12 weeks (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-15
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 142 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Instituto Dante Pazzanese de Cardiologia
Collaborators: Servier
Contact Information
Study Contact:
Antonio G Laurinavicius, MD, PhD
5511996695389
antonio.laurinavicius@gmail.com
Interventions
  • Drug: Triple Fixed-Dose Combination (Perindoprile/Indapamide/Amlodipine) — Participants receive a fixed-dose tablet containing perindopril 10 mg, indapamide 2.5 mg, and amlodipine 10 mg administered once daily for 12 weeks. Randomized participants in this group discontinue their previous antihypertensive medications and replace them with the single-pill triple fixed-dose combination. Treatment adjustments may be made if required according to office blood pressure measurements
  • Drug: Usual Care Antihypertensive Regimen — Participants continue their usual antihypertensive therapy, consisting of up to five drug classes administered as separate tablets. Medication types and doses are adjusted by the investigator as needed to achieve office blood pressure control, following standard clinical practice. Treatment modifications are permitted throughout the 12-week study period according to clinical judgment and blood pressure response.
Study Locations (1 sites)
Instituto Dante Pazzanese de Cardiologia, São Paulo, São Paulo 04012909 Brazil
Eligibility Criteria
Inclusion Criteria: Age between 18 and 75 years; Treatment with 3 to 5 classes of antihypertensive drugs, including a maximum dose of an ACE inhibitor or ARB, a thiazide or thiazide-like diuretic, and a calcium channel blocker (CCB); Recent 24-hour ambulatory blood pressure monitoring (ABPM) (\<1 month) showing values above target (24-hour BP ≥130/80 mmHg); Office blood pressure ≥140/90 mmHg; Poor adherence to treatment, defined as a score ≥1 point on the Morisky Medication Adherence Scale (MMAS-4). \- Exclusion Criteria:Secondary hypertension (including hyperaldosteronism, pheochromocytoma, or renovascular hypertension); History of intolerance or adverse reactions to study medications, such as ACE inhibitors (cough or angioedema), thiazide or thiazide-like diuretics (electrolyte disturbances), or calcium channel blockers (significant ankle edema or headache); Indispensable use of beta-blockers or mineralocorticoid receptor antagonists; Office blood pressure ≥ 220 × 120 mmHg; Reduced left ventricular ejection fraction (LVEF \< 55%); Severe renal impairment (creatinine clearance \< 30 mL/min or eGFR \< 30 mL/min/1.73 m²); Atrial fibrillation or atrial flutter; Use of oral anticoagulants; Significant valvular heart disease; Body mass index (BMI) ≥ 40 kg/m²; Pregnant or breastfeeding women; Severe psychiatric disorders; Active malignancy with life expectancy \< 2 years; \-